Skip to content
Peptideworth

Provider review

AHBARx Review: The Most Carefully Hedged Claims Here, About the Same Untested Things

AHBARx is the most linguistically careful seller in this batch. Its peptides are "intended to support" and "may help" rather than promised to work, and its sermorelin card opens with a mechanism that is simply correct. None of that changes the evidence underneath: a hedge alters the confidence of a sentence, not the literature behind it, and "may support detoxification" points at the same empty search as the unhedged version. It also names a partner that holds an FDA warning letter, and calls that partner a provider group when FDA calls it a pharmacy.

The most carefully worded claims in this batch, hedged over exactly the same absent literature — and a named partner that FDA has written to, described here as something it is not.

Worth trusting if

  • You want a seller that writes "may support" rather than asserting an effect it cannot show
  • You want the prescribing groups named, and the founder named with credentials
  • You are buying sermorelin and reading only its first sentence, which is accurate

Be skeptical if

  • You want to know which pharmacy compounds your prescription, because the terms leave the list blank
  • You want a lab result for what you are injecting, because none is published
  • You read "may support" as evidence, because on two of these three products there is none
Dispenses

Compounded only

Evidence

No trial for this use

Pharmacy

Not named

FDA letter

None found

By Grant Delaney, Research Editor

Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.

Visit AHBARx

Opens ahbarx.com. A link is not a recommendation to take anything.

Provenance

What AHBARx actually dispenses

Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.

Compounded (503A)3 products

Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

  • Sermorelin Acetate Injection, 9mg/vial$299 for a one-month supply, delivered monthly.
  • NAD+ liquid$299 for a one-month supply, the dearest peptide here.
  • Glutathione, 200mg/mL$199 for a 5mL vial, or $299 for 30mL delivered quarterly.

Evidence

Has the molecule been tested for what it is sold for?

One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.

Sermorelin · compounded
No trial for this use
NAD+ (nicotinamide adenine dinucleotide) · compounded
No trial for this use
Glutathione · compounded
No trial for this use

0

Molecules with human evidence

For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to AHBARx.

0

Registry records cited

Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.

The comparison

What they claim, against what the trials show

Each claim below is quoted verbatim from AHBARx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.

Sermorelin Acetate Injection, 9mg/vialSermorelin · Compounded (503A)Claim reaches past the trials
Sermorelin Acetate is a peptide therapy designed to stimulate natural growth hormone production. It may help adults maintain energy, recovery, and overall wellness under the supervision of a licensed healthcare provider.

Read on the AHBARx site, September 2026

No trial for this use

What the trials show for Sermorelin

As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests energy, recovery or wellness as an outcome in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.

The first sentence is right and the second is a hedge over an absence. "Designed to stimulate natural growth hormone production" is accurate — that is the molecule's mechanism and what all nineteen randomized trials measured. "May help adults maintain energy, recovery, and overall wellness" names three outcomes that were never measured in any of them. The word "may" is doing honest work about uncertainty and no work at all about evidence: a reader still comes away believing energy and recovery are on the table.1

NAD+ liquidNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
NAD⁺ is a coenzyme-based therapy intended to support cellular energy, metabolic processes, and overall wellness. It is designed for adults seeking guidance on energy, focus, and overall cellular health under the supervision of a licensed healthcare provider.

Read on the AHBARx site, September 2026

No trial for this use

As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.

Five outcomes across two sentences — cellular energy, metabolic processes, wellness, focus and cellular health — and not one has a completed randomized trial of injected NAD+ behind it. "Intended to support" and "designed for adults seeking" are careful constructions that describe what the seller means the product to do rather than what anyone has shown it does, and the distinction is invisible to a reader deciding whether to spend $299.2

Glutathione, 200mg/mLGlutathione · Compounded (503A)No trial supports this claim
Glutathione is an antioxidant naturally produced in the body that may support cellular protection, detoxification, and skin wellness, helping you feel refreshed and energized under the guidance of a licensed healthcare provider.

Read on the AHBARx site, September 2026

No trial for this use

What the trials show for Glutathione

As of August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned seven records. Not one tests injected glutathione on its own for any of those outcomes. On ClinicalTrials.gov, 268 studies list glutathione as an intervention; restricting to injected routes returns three, in mantle-cell lymphoma, acute liver failure and pneumonia.

The opening clause is the only true part and it is a fact about biology, not about the product: glutathione is indeed an antioxidant the body makes. Everything after "may support" — cellular protection, detoxification, skin wellness, feeling refreshed and energized — describes outcomes no trial of injected glutathione in a healthy adult has measured. The sentence ends by promising a feeling, which is the least checkable claim a seller can make.3

Dispensing chain

Who actually fills your prescription

Pharmacy not named
Read the full account

AHBARx names three partners and none of them is presented accurately as its dispensing pharmacy. Its Help Center says "All medical services are provided by licensed, independent professionals – Beluga Health, AnazaoHealth, and Qualiphy, a LegitScript-certified provider group." Beluga Health and Qualiphy are telehealth platforms and medical groups; AnazaoHealth is a 503B outsourcing facility, which is a pharmacy, and calling it a provider group misdescribes what it does. AnazaoHealth Corporation also holds FDA warning letter #613214, issued 2021-08-18 and headed "Compounding Pharmacy/Adulterated Drug Products" — matched on entity and address, and it names neither AHBARx nor Ahura Wellness. A warning letter is a public regulatory communication rather than a finding of illegal activity, and it belongs to that pharmacy, not to this company. Meanwhile the Terms' own pharmacy list is an unfilled template reading "[list of Pharmacies]", so the site never states which pharmacy compounds a given prescription. The founder is named with credentials: Dr. Nima Yazdanpanah, DO, QME.

Read on the AHBARx site, September 2026.

Quality

Third-party testing, and what is published

Describes a testing regime

Nothing published on the pages searched

Certificate of analysis readable

No lot report a buyer can open

Read the full testing account

No certificate of analysis, potency, purity or sterility result is published for any peptide. A collapsed homepage FAQ says medications are "sourced through U.S.-based, FDA-registered compounding pharmacies", which describes a registration status rather than a test — and note that registration under section 503B is not an approval and confers no quality finding on any product. The site's own Terms were meant to list the pharmacies and the laboratories and list neither, both fields still reading as bracketed placeholders.

Read on the AHBARx site, September 2026.

Licensing

Licensed to dispense, and where

Coverage

AHBARx says in its footer, terms and privacy policy that "services are available only to patients physically located within all 50 states of the United States", and its checkout state selector enumerates 51 entries — the 50 states plus the District of Columbia. Its privacy policy pulls the other way, saying the service "may only be used within certain states within the United States as described in our Terms and Conditions", and the terms name no state at all.

Read the full licensing claim

"All medical services are provided by licensed, independent professionals – Beluga Health, AnazaoHealth, and Qualiphy", with the founder named as Dr. Nima Yazdanpanah, DO, QME. No state license number is published, and the Terms' pharmacy, laboratory and medical-group lists are unfilled placeholders.

Read on the AHBARx site, September 2026.

Regulatory

The FDA warning letter

Checked, and none found

A search of the 113 warning letters issued to telehealth firms in the September 9, 2025, February 20, 2026 and June 8, 2026 enforcement waves — matched on full company name rather than substring, because a substring match attaches one company’s regulatory history to another — returns no entry for AHBARx (Ahura Wellness P.C.). That is a statement about those three waves as of September 2026, not a claim that no action exists anywhere.

Assessment

What holds up, and what does not

What holds up
  • Its claims are hedged rather than asserted — "intended to support", "may help", "may support" — which is more careful language than almost anything else in this category.
  • Its sermorelin card opens with an accurate mechanism: designed to stimulate natural growth hormone production, which is what nineteen randomized trials measured.
  • It names its prescribing partners — Beluga Health and Qualiphy — and its founder, Dr. Nima Yazdanpanah, DO, QME, with credentials.
Show 4 more
  • Its glutathione claim opens by correctly describing the molecule as one the body already produces, rather than implying it is a foreign drug with a novel action.
  • Prices and supply lengths are on each product page before any account or questionnaire.
  • Its LegitScript certification resolves for this domain.
  • No FDA warning letter against AHBARx or Ahura Wellness.
What does not
  • A partner it names holds an FDA warning letter it never mentions: AnazaoHealth Corporation, cited in 2021 over adulterated compounded drug products.
  • It calls AnazaoHealth a "provider group". FDA identifies it as a 503B outsourcing facility — a pharmacy, not a medical group.
  • Its terms were meant to name its pharmacies, laboratories and medical groups and name none: all three lists are still bracketed placeholders.
Show 5 more
  • No certificate of analysis, potency or purity result is published for any peptide.
  • Two of its three peptide claims name five and four outcomes respectively, none of which has a completed trial behind it.
  • "May support" changes the confidence of a sentence and not the evidence under it — a reader still comes away believing the outcome is available.
  • Its glutathione claim ends by promising a feeling — "refreshed and energized" — which is the least checkable thing a seller can offer.
  • Its legal pages do not name the operating entity; "Ahura Wellness P.C." appears only in the Help Center and About page.

Verdict

The bottom line

Read the first clause of each card and stop there. On sermorelin that clause is accurate — it does stimulate growth hormone release. On NAD+ and glutathione the true part is a description of a molecule the body already contains, and everything after "may support" is untested. Then look up AnazaoHealth before you buy: AHBARx names it as a partner, describes it as a provider group when it is a compounding pharmacy, and does not mention the 2021 warning letter it holds.

Visit AHBARx

Opens ahbarx.com. A link is not a recommendation to take anything.

Careful language, unchanged evidence

AHBARx is the most linguistically cautious seller in this batch, and it is worth being precise about what that buys.

Sermorelin — "designed to stimulate natural growth hormone production. It may help adults maintain energy, recovery, and overall wellness."

NAD+ — "a coenzyme-based therapy intended to support cellular energy, metabolic processes, and overall wellness."

Glutathione — "an antioxidant naturally produced in the body that may support cellular protection, detoxification, and skin wellness."

Compare that with the sellers in this sweep who write "supports detoxification, immune function and skin clarity" flat, with no hedge at all.

And then notice that the searches return the same thing either way.

A hedge changes the confidence of a sentence. It does not change the literature behind it. "May support detoxification" and "supports detoxification" point at the identical empty result set — seven randomized records for injected glutathione, none testing the drug on its own. 3 A reader deciding whether to spend $199 reads both sentences as a reason to buy.

Where the caution genuinely earns something is the sermorelin card's first clause. "Designed to stimulate natural growth hormone production" is simply correct: that is the mechanism, and it is what all nineteen randomized trials measured. 1 The second sentence then names energy, recovery and wellness, which were an outcome in none of them.

So: one accurate clause, hedged sentences over two absences, and a house style that makes the difference harder to see rather than easier.

Full analysis — 3 more sectionsThe partner it names, and what it calls it · The lists that were never filled in · What is not published

The partner it names, and what it calls it

"All medical services are provided by licensed, independent professionals – Beluga Health, AnazaoHealth, and Qualiphy, a LegitScript-certified provider group."

Beluga Health and Qualiphy are telehealth platforms. AnazaoHealth is a 503B outsourcing facility — a compounding pharmacy that registers with FDA and is subject to inspection and CGMP. Calling it a provider group describes it as something it is not, and it is the one of the three most likely to have touched the vial.

AnazaoHealth Corporation also holds FDA warning letter #613214, issued 18 August 2021 and headed "Compounding Pharmacy/Adulterated Drug Products". We matched it on entity and address; the letter names neither AHBARx nor Ahura Wellness, and a warning letter is a public regulatory communication rather than a finding of illegal activity. It belongs to that pharmacy. AHBARx does not mention it.

The lists that were never filled in

AHBARx's Terms of Use contain a section that was written to name its supply chain. It currently reads, in full:

"Our Service provides access to prescription fulfillment services offered by the following pharmacies: [list of Pharmacies] … laboratories: [list of Labs] … medical groups … [list of Medical Groups]"

Also unfilled: "[phone number]", "[support@ahbarx.com]", and "[www.ahbarx.com]" — the company's own address, in brackets, in its own contract.

That is a fact about what the operator configured rather than an accusation. Its consequence for a buyer is concrete: the document that was supposed to tell you which pharmacy compounds your prescription does not, and no other page does either.

What is not published

No certificate of analysis. No potency result. No purity result. No named dispensing pharmacy.

The nearest thing to a quality statement is a collapsed FAQ saying medications are "sourced through U.S.-based, FDA-registered compounding pharmacies". Registration under 503B is real, and it is not an approval: it means the facility is subject to inspection, not that any product has been evaluated.

Questions

Frequently asked questions

Does hedged language make a claim more accurate?

It makes it more honest about uncertainty and no more supported. "May support detoxification" and "supports detoxification" rest on the same seven randomized records, none of which tests injected glutathione on its own. AHBARx writes more carefully than most sellers here; the evidence behind two of its three peptides is unchanged by that.

Which AHBARx claim is accurate?

The first clause of its sermorelin card. "Designed to stimulate natural growth hormone production" is the molecule's mechanism and is exactly what all nineteen randomized trials measured. The energy, recovery and wellness that follow it were an outcome in none of them.

Does AHBARx hold an FDA warning letter?

No, but a partner it names does. AnazaoHealth Corporation — listed on AHBARx's site alongside Beluga Health and Qualiphy — received a warning letter in August 2021 headed "Compounding Pharmacy/Adulterated Drug Products". It names neither AHBARx nor Ahura Wellness, and a warning letter is a regulatory communication rather than a finding of illegal activity.

Which pharmacy compounds these peptides?

The site never says. Its Terms contain a section written to list them and it is still an unfilled placeholder reading "[list of Pharmacies]", alongside empty brackets for its laboratories, its medical groups, its phone number and its own web address. AnazaoHealth is named elsewhere as a partner, and described there as a provider group rather than the pharmacy it is.

Does it publish test results?

No certificate of analysis, potency or purity result appears for any peptide. Its FAQ says medications are sourced through FDA-registered compounding pharmacies, which describes a facility's registration status rather than a test of the product you receive.

Glossary

Key terms

Show definitions
503B outsourcing facility
A compounder that registers with FDA and is subject to inspection and current good manufacturing practice. Registration is not approval, and a 503B facility is a pharmacy rather than a medical group.
FDA-registered
A statement that a facility has told FDA it exists and accepted inspection. It says nothing about whether any particular product has been evaluated for safety, effectiveness or quality.

Compare

Others selling what AHBARx sells

Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.

Method

How we checked this

Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.

Read our methodology

Claims read first-party

Every quoted claim was read off AHBARx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.

Trials read from the registry

Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.

Absence claims bounded

Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.

Letters matched on full name

FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.

Sources

References

Show all 4 sources
  1. US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
  2. US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
  3. US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND injected route AND (skin OR detoxification OR fatigue OR energy) AND randomized controlled trial[pt] — 7 records, none testing injected glutathione alone; ClinicalTrials.gov injected-route glutathione — 3 studies, in lymphoma, acute liver failure and pneumonia. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
  4. US Food and Drug Administration (2021). Warning Letter #613214 to AnazaoHealth Corporation, 7465 W. Sunset Road Suite 1200, Las Vegas NV — issued 2021-08-18, subject "Compounding Pharmacy/Adulterated Drug Products". FDA Inspections, Compliance, Enforcement and Criminal Investigations. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anazaohealth-corporation-613214-08182021

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.